KDR and neoplasm: CSF1R, paradoxically associated with favorable prognosis in DLBCL, remains a therapeutic target for reprogramming M2-tumor-associated macrophages (TAMs), as shown by SYHA1813’s (a VEGFR and CSF1R inhibitor) efficacy against Bruton’s tyrosine kinase inhibitor (BTKi) resistance [30].